Entero Healthcare aims to grow its medical devices revenue to over ₹1,000 crore by FY27, shifting focus toward higher-value products. The company recently reported a 38% rise in Q1 FY27 revenue, hitting a 5% profit margin target early. With the stock recently reaching a 52-week high, investors are now evaluating whether the company can sustain this growth while managing the integration of its newer business lines.
Entero Healthcare is actively reshaping its business model, moving from traditional pharmaceutical distribution toward the higher-margin medical devices segment. The company has set an internal goal for its medical technology business to exceed ₹1,000 crore in annual revenue by FY27. This sector currently makes up about 15% of the company's total sales, but management plans to increase that share to 20% over the next two to three years.
This shift is primarily driven by a need for better profit margins. Pharmaceutical distribution is a high-volume, highly competitive business where distributors often have limited control over pricing. In contrast, the medical device sector involves more business development and specialized supply chain management, resulting in fewer distributors and stronger commercial relationships. By increasing its exposure to these devices, the company hopes to improve its overall profitability.
Financial performance in the first quarter of FY27 has provided some support for this strategy. The company reported consolidated revenue of ₹1,940.5 crore, representing a 38% increase compared to the same period last year. Additionally, Entero Healthcare achieved an operating profit margin of 5.0% in this quarter, effectively reaching its full-year guidance for FY27 earlier than expected.
The stock market has responded to these developments with significant interest. Driven by strong quarterly results and the updated guidance, the share price rallied by roughly 50% over the past month, recently touching a 52-week high. However, this sharp rise has pushed the company's valuation to approximately 30 times its estimated FY28 earnings, suggesting that investors have already priced in high expectations for future growth.
While the expansion into medical devices offers potential, it also brings specific business risks. Managing this growth requires the company to successfully integrate multiple acquisitions and navigate the unique working capital needs of the medical device industry, which can sometimes be more demanding than pharmaceutical distribution. If the company fails to maintain its current momentum or if integration costs rise, it could put pressure on margins and the stock's premium valuation.
Investors will likely track whether the company can maintain its 23% organic revenue growth guidance and successfully scale its medical devices segment in the coming quarters. The primary focus for the market will be on whether the company can balance its rapid expansion with consistent execution and efficient use of capital.